XML 66 R61.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting - Schedule of Segment Reported Segment Revenues, and Significant (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2025
Sep. 30, 2024
Segment Reporting Information [Line Items]                
Revenues $ 13,129     $ 9,300     $ 36,219 $ 11,564
Operating costs and expenses:                
Cost of product revenue [1] 1,088     806     2,607 894
Pemivibart 333     4,637     2,629 27,936
VYD2311 265     45,045     2,778 64,175
Adintrevimab 41     128     368 475
Total direct, external research and development expenses by program 639     49,810     5,775 92,586
Unallocated research and development expenses(1) [2] 6,585     7,108     20,046 23,261
Other segment items(2) [3] 12,767     11,021     41,717 35,739
Stock based compensation expense 3,073     2,866     9,079 16,731
Total operating costs and expenses 24,152     71,611     79,224 169,211
Loss from operations (11,023)     (62,311)     (43,005) (157,647)
Other income:                
Other income, net [4] 553     1,572     1,586 6,165
Total other income, net 553     1,572     1,586 6,165
Net Income (Loss) (10,470) $ (14,660) $ (16,289) (60,739) $ (47,247) $ (43,496) (41,419) (151,482)
Product [Member]                
Segment Reporting Information [Line Items]                
Revenues $ 13,129     $ 9,300     $ 36,219 $ 11,564
[1] Includes related-party amounts of $525 and $1,449 for the three and nine months ended September 30, 2025, respectively, and related-party amounts of $463 for both the three and nine months ended September 30, 2024 (see Note 15).
[2] Includes personnel related expenses (excluding research and development stock-based compensation) and external discovery-related and other costs.
[3] Includes commercial, general and administrative personnel related costs (excluding stock-based compensation), professional and consulting fees and other costs.
[4] Includes interest income of $554 and $1,563 for the three months ended September 30, 2025 and 2024, respectively and interest income of $1,587 and $6,325 for the nine months ended September 30, 2025 and 2024, respectively.